Candel Therapeutics (CADL) EBITDA (2020 - 2025)

Candel Therapeutics' EBITDA history runs 6 years deep, the most recent figure standing at -$15.8 million for Q4 2025.

• In Q4 2025, EBITDA fell 93.49% year-over-year to -$15.8 million; the TTM figure through Dec 2025 stood at -$48.3 million (down 44.63% YoY), while the FY2025 annual figure was -$48.3 million, down 44.63% from the prior year.
• EBITDA came in at -$15.8 million for Q4 2025 at Candel Therapeutics, down from -$13.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.6 million in Q4 2021 to a low of -$17.1 million in Q2 2021.
• A 5-year average of -$9.6 million and a median of -$8.9 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 115.16% in 2021 and plunged 607.58% in 2022, its largest moves.
• Candel Therapeutics' EBITDA stood at $1.6 million in 2021, then slumped by 607.58% to -$8.1 million in 2022, then decreased by 27.37% to -$10.3 million in 2023, then increased by 21.1% to -$8.1 million in 2024, then slumped by 93.49% to -$15.8 million in 2025.
• According to Business Quant data, EBITDA over the past three periods registered -$15.8 million, -$13.2 million, and -$11.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison